All In Biotech

Drug Trial Radar · NCT00863681

BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension

Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg,1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)

Last checked: Nov 20, 2026Latest source record: Nov 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

396

Actual

Start

Mar 12, 2009

Primary completion

Aug 19, 2019

Study completion Aug 19, 2019

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Mar 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934) will be asked to participate in this long term extension study with BAY63-2521.

Conditions

  • Hypertension, Pulmonary

Interventions

  • Riociguat (BAY63-2521)Drug

    BAY63-2521: 1mg tid -2.5 mg tid oral until end of study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAE)Time frame: From administration of first dose of study medication in PATENT-2 up to 2 days after end of treatment with study medication, up to 10 years and 5 months.
  2. Number of Participant With DeathTime frame: From baseline to end of safety follow-up visit, up to 10 years and 6 months (1 month more than End of study visit)

Locations

99 sites in 27 countries. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

  • Site not named

    Sacramento, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Omaha, Nebraska

  • Site not named

    Cleveland, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Fairfield, Ohio

  • Site not named

    Dallas, Texas

  • Site not named

    El Paso, Texas

  • Site not named

    Capital Federal, Argentina

  • Site not named

    Darlinghurst, New South Wales, Australia

  • Site not named

    Auchenflower, Queensland, Australia

  • Site not named

    Herston, Queensland, Australia

  • Site not named

    Hobart, Tasmania, Australia

  • Site not named

    Prahran, Victoria, Australia

  • Site not named

    Innsbruck, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Linz, Upper Austria, Austria

  • Site not named

    Bruxelles - Brussel, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Rio de Janeiro, Brazil

  • Site not named

    Porto Alegre, Rio Grande do Sul, Brazil

  • Site not named

    São Paulo, São Paulo, Brazil

  • Site not named

    São Paulo, São Paulo, Brazil

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Shanghai, China

  • Site not named

    Shanghai, China

  • Site not named

    Guangzhou, Guangdong, China

  • Site not named

    Prague, Czechia

  • Site not named

    Aarhus N, Denmark

  • Site not named

    Besançon, France

  • Site not named

    Brest, France

  • Site not named

    Grenoble, France

  • Site not named

    Lille, France

  • Site not named

    Montpellier, France

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.